Online Bullying Bystander Intervention for Middle Schools Phase II
Launched by KLEIN BUENDEL, INC. · Oct 6, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
While studies support the efficacy of comprehensive, school-wide interventions in reducing bullying, these types of programs can require significant time and financial resources for implementation, resulting in barriers to providing school-based bullying prevention, especially in low-income and rural communities. Additionally, although training bystanders to act as "defenders" on behalf of targets of bullying is an important intervention component, few programs include this as part of their comprehensive strategy. Brief programs that focus on bystander training and require fewer resources a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria for Students:
- • being enrolled in grades 6, 7, or 8 in a middle/junior high school in Idaho, Oregon, Mississippi, or New Hampshire.
- • being selected by school counselors and teachers for having a desire to make a positive difference at school, be mature, and have the ability to positively engage with peers and adults (Aims 1 and 2).
- • speaks and reads English or Spanish.
- • parent consents and student assents for participation.
- Exclusion Criteria for Students:
- • participated in a previous study on STAC.
- • speaks and reads only a language other than English or Spanish.
- • does not consent and/or assent for participation.
- Inclusion Criteria for School Personnel:
- • employed in a middle/junior high school in Idaho or Mississippi with grades 6, 7, or 8.
- • employed as a principal, teacher, or school counselor.
- • speaks and reads English or Spanish.
- • consents to participate.
- Exclusion Criteria for School Personnel:
- • participated in a previous study on STAC.
- • speaks and reads only a language other than English or Spanish.
- • does not consent for participation.
About Klein Buendel, Inc.
Klein Buendel, Inc. is a specialized clinical trial sponsor dedicated to advancing health outcomes through innovative research and development. With a focus on behavioral interventions, the company leverages its expertise in health communication and technology to design and implement rigorous clinical studies. Klein Buendel collaborates with academic institutions and healthcare organizations to address critical health challenges, ensuring that their research is grounded in scientific excellence and real-world applicability. Committed to enhancing public health, the organization prioritizes the ethical conduct of research and the dissemination of findings to inform best practices in clinical care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boise, Idaho, United States
University, Mississippi, United States
Patients applied
Trial Officials
Mary Buller, MA
Principal Investigator
Klein Buendel, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials